Effects of d-cycloserine on MPTP-induced behavioral and neurological changes: Potential for treatment of Parkinson's disease dementia

Behavioural Brain Research

Volumn 219, Issue 2, 2011, Pages 280-290

  Ho, Ying Jui ^a   Ho, Shih Chun ^a   Pawlak, Cornelius Rainer ^b,c   Yeh, Kuei Ying ^d  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

Cognition; D Cycloserine; Dementia; Neuroinflammation; NMDA receptor; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYCLOSERINE; INTERLEUKIN 2;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORPUS STRIATUM; DEMENTIA; DOPAMINERGIC NERVE CELL; DRUG EFFECT; HIPPOCAMPAL CA1 REGION; MALE; MAZE TEST; MEMORY DISORDER; MICROGLIA; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; ROTAROD TEST; WORKING MEMORY;

ANIMALS; ANXIETY; BRAIN; CYCLOSERINE; DEMENTIA; HIPPOCAMPUS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; MALE; MAZE LEARNING; MICROGLIA; MPTP POISONING; PARKINSON DISEASE; POSTURAL BALANCE; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY);

EID: 79952704032     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.01.028     Document Type: Article

References (106)

1. Aarsland D., Andersen K., Larsen J.P., Lolk A., Nielsen H., Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001, 56:730-736.
2. Abramsky O., Litvin Y. Autoimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia. Perspect Biol Med 1978, 22:104-114.
3. Aggleton J.P., Mishkin M. Visual recognition impairment following medial thalamic lesions in monkeys. Neuropsychologia 1983, 21:189-197.
4. Ando S., Kobayashi S., Waki H., Kon K., Fukui F., Tadenuma T., et al. Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. J Neurosci Res 2002, 70:519-527.
5. Ando S., Ohashi Y. Longitudinal study on age-related changes of working and reference memory in the rat. Neurosci Lett 1991, 128:17-20.
6. Baxter M.G., Lanthorn T.H., Frick K.M., Golski S., Wan R.Q., Olton D.S. d-Cycloserine, a novel cognitive enhancer, improves spatial memory in aged rats. Neurobiol Aging 1994, 15:207-213.
7. Billard J.M., Rouaud E. Deficit of NMDA receptor activation in CA1 hippocampal area of aged rats is rescued by d-cycloserine. Eur J Neurosci 2007, 25:2260-2268.
8. Bonuccelli U., Del Dotto P. New pharmacologic horizons in the treatment of Parkinson disease. Neurology 2006, 67:S30-S38.
9. Bortolanza M., Wietzikoski E.C., Boschen S.L., Dombrowski P.A., Latimer M., Maclaren D.A., et al. Functional disconnection of the substantia nigra pars compacta from the pedunculopontine nucleus impairs learning of a conditioned avoidance task. Neurobiol Learn Mem 2010, 94:229-239.
10. Bosboom J.L., Stoffers D., Wolters E. Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 2004, 111:1303-1315.
11. Broadbent N.J., Squire L.R., Clark R.E. Spatial memory, recognition memory, and the hippocampus. Proc Natl Acad Sci USA 2004, 101:14515-14520.
12. Brown R.G., Marsden C.D. How common is dementia in Parkinson's disease?. Lancet 1984, 2:1262-1265.
13. Capitelli C., Sereniki A., Lima M.M., Reksidler A.B., Tufik S., Vital M.A. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol 2008, 594:101-108.
14. Caraceni A., Martini C., Belli F., Mascheroni L., Rivoltini L., Arienti F., et al. Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. Eur J Cancer 1993, 29A:1266-1269.
15. Chassain C., Bielicki G., Durand E., Lolignier S., Essafi F., Traore A., et al. Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse. J Neurochem 2008, 105:874-882.
16. Crucian G.P., Okun M.S. Visual-spatial ability in Parkinson's disease. Front Biosci 2003, 8:s992-s997.
17. Da Cunha C., Gevaerd M.S., Vital M.A., Miyoshi E., Andreatini R., Silveira R., et al. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res 2001, 124:9-18.
18. Da Cunha C., Wietzikoski S., Wietzikoski E.C., Miyoshi E., Ferro M.M., Anselmo-Franci J.A., et al. Evidence for the substantia nigra pars compacta as an essential component of a memory system independent of the hippocampal memory system. Neurobiol Learn Mem 2003, 79:236-242.
19. Denicoff K.D., Rubinow D.R., Papa M.Z., Simpson C., Seipp C.A., Lotze M.T., et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987, 107:293-300.
20. Duncan E.J., Szilagyi S., Schwartz M.P., Bugarski-Kirola D., Kunzova A., Negi S., et al. Effects of d-cycloserine on negative symptoms in schizophrenia. Schizophr Res 2004, 71:239-248.
21. Duva C.A., Floresco S.B., Wunderlich G.R., Lao T.L., Pinel J.P., Phillips A.G. Disruption of spatial but not object-recognition memory by neurotoxic lesions of the dorsal hippocampus in rats. Behav Neurosci 1997, 111:1184-1196.
22. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003, 2:229-237.
23. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 1988, 31:47-59.
24. Ferro M.M., Angelucci M.E., Anselmo-Franci J.A., Canteras N.S., Da Cunha C. Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease. Braz J Med Biol Res 2007, 40:89-96.
25. Ferro M.M., Bellissimo M.I., Anselmo-Franci J.A., Angellucci M.E., Canteras N.S., Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Meth 2005, 148:78-87.
26. Gevaerd M.S., Takahashi R.N., Silveira R., Da Cunha C. Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats. Brain Res Bull 2001, 55:101-106.
27. Girotti F., Soliveri P., Carella F., Piccolo I., Caffarra P., Musicco M., et al. Dementia and cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988, 51:1498-1502.
28. Goetz C.G. New lessons from old drugs: amantadine and Parkinson's disease. Neurology 1998, 50:1211-1212.
29. Greenamyre J.T., O'Brien C.F. N-Methyl-d-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991, 48:977-981.
30. Guastella A.J., Dadds M.R., Lovibond P.F., Mitchell P., Richardson R. A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. J Psychiatr Res 2007, 41:466-471.
31. Hammond R.S., Tull L.E., Stackman R.W. On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem 2004, 82:26-34.
32. Heresco-Levy U., Kremer I., Javitt D.C., Goichman R., Reshef A., Blanaru M., et al. Pilot-controlled trial of d-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2002, 5:301-307.
33. Ho Y.J., Hsu L.S., Wang C.F., Hsu W.Y., Lai T.J., Hsu C.C., et al. Behavioral effects of d-cycloserine in rats: the role of anxiety level. Brain Res 2005, 1043:179-185.
34. Ho Y.J., Wang C.F., Hsu W.Y., Tseng T., Hsu C.C., Kao M.D., et al. Psychoimmunological effects of dioscorea in ovariectomized rats: role of anxiety level. Ann Gen Psychiatry 2007, 6:21-28.
35. Hofmann S.G., Meuret A.E., Smits J.A., Simon N.M., Pollack M.H., Eisenmenger K., et al. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006, 63:298-304.
36. Hofmann S.G., Pollack M.H., Otto M.W. Augmentation treatment of psychotherapy for anxiety disorders with d-cycloserine. CNS Drug Rev 2006, 12:208-217.
37. Hood W.F., Compton R.P., Monahan J.B. d-Cycloserine: a ligand for the N-methyl-d-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 1989, 98:91-95.
38. Hughes R.N. Responsiveness to brightness change in male and female rats following treatment with the partial agonist of the N-methyl-d-aspartate receptor, d-cycloserine. Behav Brain Res 2004, 152:199-207.
39. Hunsaker M.R., Thorup J.A., Welch T., Kesner R.P. The role of CA3 and CA1 in the acquisition of an object-trace-place paired-associate task. Behav Neurosci 2006, 120:1252-1256.
40. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 2003, 106:518-526.
41. Inzelberg R., Bonuccelli U., Schechtman E., Miniowich A., Strugatsky R., Ceravolo R., et al. Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord 2006, 21:1375-1379.
42. Karrenbauer B.D., Ho Y.J., Ludwig V., Löohn J., Spanagel R., Schwarting R.K., et al. Time-dependent effects of striatal interleukin-2 on open field behaviour in rats. J Neuroimmunol 2009, 208:10-18.
43. Kawabe K., Yoshihara T., Ichitani Y., Iwasaki T. Intrahippocampal d-cycloserine improves MK-801-induced memory deficits: radial-arm maze performance in rats. Brain Res 1998, 814:226-230.
44. Kim Y.S., Joh T.H. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 2006, 38:333-347.
45. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 1998, 39:167-180.
46. Laake K., Oeksengaard A.R. d-Cycloserine for Alzheimer's disease. Coch Data Sys Rev 2002, CD003153.
47. Laatu S., Revonsuo A., Pihko L., Portin R., Rinne J.O. Visual object recognition deficits in early Parkinson's disease. Parkinsonism Relat Disord 2004, 10:227-233.
48. Lacosta S., Merali Z., Anisman H. Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety. Behav Neurosci 1999, 113:1030-1041.
49. Land C., Riccio D.C. d-cycloserine: effects on long-term retention of a conditioned response and on memory for contextual attributes. Neurobiol Learn Mem 1999, 72:158-168.
50. Lanthorn T.H. d-Cycloserine: agonist turned antagonist. Amino Acids 1994, 6:247-260.
51. Lee Y.T., Wang W.F., Cheng C.W., Wu S.L., Pawlak C.R., Ho Y.J. Effects of escapable and inescapable stressors on behavior and interleukin-2 in the brain. Neuroreport 2008, 19:1243-1247.
52. Lelong V., Dauphin F., Boulouard M. RS 67333 and d-cycloserine accelerate learning acquisition in the rat. Neuropharmacology 2001, 41:517-522.
53. Levin B.E., Llabre M.M., Reisman S., Weiner W.J., Sanchez-Ramos J., Singer C., et al. Visuospatial impairment in Parkinson's disease. Neurology 1991, 41:365-369.
54. Li J.S., Chao Y.S. Electrolytic lesions of dorsal CA3 impair episodic-like memory in rats. Neurobiol Learn Mem 2008, 89:192-198.
55. Licinio J., Seibyl J.P., Altemus M., Charney D.S., Krystal J.H. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 1993, 150:1408-1410.
56. Mandillo S., Rinaldi A., Oliverio A., Mele A. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav Pharmacol 2003, 14:533-544.
57. Matsuoka N., Aigner T.G. d-Cycloserine, a partial agonist at the glycine site coupled to N-methyl-d-aspartate receptors, improves visual recognition memory in rhesus monkeys. J Pharmacol Exp Ther 1996, 278:891-897.
58. McAllister C.G., van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M.E., et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995, 152:1291-1297.
59. McGeer P.L., McGeer E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004, 10(Suppl. 1):S3-S7.
60. Miyoshi E., Wietzikoski S., Camplessei M., Silveira R., Takahashi R.N., Da Cunha C. Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res Bull 2002, 58:41-47.
61. Mogi M., Harada M., Kondo T., Riederer P., Nagatsu T. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. J Neural Transm 1996, 103:1077-1081.
62. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996, 211:13-16.
63. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994, 165:208-210.
64. Mogi M., Togari A., Ogawa M., Ikeguchi K., Shizuma N., Fan D., et al. Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum. Neurosci Lett 1998, 250:25-28.
65. Mosley R.L., Benner E.J., Kadiu I., Thomas M., Boska M.D., Hasan K., et al. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clin Neurosci Res 2006, 6:261-281.
66. Nagatsu T., Mogi M., Ichinose H., Togari A. Cytokines in Parkinson's disease. J Neural Transm Suppl 2000, 143-151.
67. Nakajima K., Kohsaka S. Microglia: neuroprotective and neurotrophic cells in the central nervous system. Curr Drug Targets Cardiovasc Haematol Disord 2004, 4:65-84.
68. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005, 57:168-175.
69. Owen A.M., Sahakian B.J., Hodges J.R., Summers B.A., Polkey C.E., Robbins T.W. Dopamine-dependent frontostriatal planning deficits in early Parkinson's disease. Neuropsychology 1995, 9:126-140.
70. Pawlak C.R., Ho Y.J., Schwarting R.K., Bauhofer A. Relationship between striatal levels of interleukin-2 mRNA and plus-maze behavior in the rat. Neurosci Lett 2003, 341:205-208.
71. Pawlak C.R., Schwarting R.K. Striatal microinjections of interleukin-2 and rat behaviour in the elevated plus-maze. Behav Brain Res 2006, 168:339-344.
72. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, London.
73. Perry J.C., Hipolide D.C., Tufik S., Martins R.D., Da Cunha C., Andreatini R., et al. Intra-nigral MPTP lesion in rats: behavioral and autoradiography studies. Exp Neurol 2005, 195:322-329.
74. Petitto J.M., McCarthy D.B., Rinker C.M., Huang Z., Getty T. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J Neuroimmunol 1997, 73:183-190.
75. Petitto J.M., McNamara R.K., Gendreau P.L., Huang Z., Jackson A.J. Impaired learning and memory and altered hippocampal neurodevelopment resulting from interleukin-2 gene deletion. J Neurosci Res 1999, 56:441-446.
76. Piekema C., Kessels R.P., Mars R.B., Petersson K.M., Fernandez G. The right hippocampus participates in short-term memory maintenance of object-location associations. Neuroimage 2006, 33:374-382.
77. Plaitakis A., Shashidharan P. Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J Neurol 2000, 247(Suppl. 2):II25-II35.
78. Rajput A. Can amantadine therapy delay the onset of dementia in Parkinson's disease?. Nat Clin Pract Neurol 2006, 2:648-649.
79. Raju D.V., Ahern T.H., Shah D.J., Wright T.M., Standaert D.G., Hall R.A., et al. Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTP-treated monkey model of parkinsonism. Eur J Neurosci 2008, 27:1647-1658.
80. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., et al. Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004, 61:1136-1144.
81. Riekkinen M., Riekkinen P.J. Nicotine and d-cycloserine enhance acquisition of water maze spatial navigation in aged rats. Neuroreport 1997, 8:699-703.
82. Robinson S., Freeman P., Moore C., Touchon J.C., Krentz L., Meshul C.K. Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. Exp Neurol 2003, 180:74-87.
83. schmiTabatabaei A., Perry T.L., Hansen S., Krieger C. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice. Neurosci Lett 1992, 141:192-194.
84. Schneider J.S., Tinker J.P., Van Velson M., Giardiniere M. Effects of the partial glycine agonist d-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. Brain Res 2000, 860:190-194.
85. Schuster G.M., Schmidt W.J. d-Cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task. Eur J Pharmacol 1992, 224:97-98.
86. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001, 125:109-125.
87. Sheinin A., Shavit S., Benveniste M. Subunit specificity and mechanism of action of NMDA partial agonist d-cycloserine. Neuropharmacology 2001, 41:151-158.
88. Shi L., Adams M.M., Long A., Carter C.C., Bennett C., Sonntag W.E., et al. Spatial learning and memory deficits after whole-brain irradiation are associated with changes in NMDA receptor subunits in the hippocampus. Radiat Res 2006, 166:892-899.
89. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., O'Callaghan J.P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J 2006, 20:670-682.
90. Stanic D., Finkelstein D.I., Bourke D.W., Drago J., Horne M.K. Time course of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur J Neurosci 2003, 18:1175-1188.
91. Stern Y., Tetrud J.W., Martin W.R., Kutner S.J., Langston J.W. Cognitive change following MPTP exposure. Neurology 1990, 40:261-264.
92. Sy H.N., Wu S.L., Wang W.F., Chen C.H., Huang Y.T., Liou Y.M., et al. MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus. Pharmacol Biochem Behav 2010, 95:158-165.
93. Temple M.D., Hamm R.J. Chronic, post-injury administration of d-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury. Brain Res 1996, 741:246-251.
94. Turski L., Bressler K., Rettig K.J., Loschmann P.A., Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-d-aspartate antagonists. Nature 1991, 349:414-418.
95. Voss J., Sanchez C., Michelsen S., Ebert B. Rotarod studies in the rat of the GABAA receptor agonist gaboxadol: lack of ethanol potentiation and benzodiazepine cross-tolerance. Eur J Pharmacol 2003, 482:215-222.
96. Wang A.L., Liou Y.M., Pawlak C.R., Ho Y.J. Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats. Behav Brain Res 2010, 208:38-46.
97. Wang T., Pei Z., Zhang W., Liu B., Langenbach R., Lee C., et al. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J 2005, 19:1134-1136.
98. Wang W.F., Wu S.L., Liou Y.M., Wang A.L., Pawlak C.R., Ho Y.J. MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats. Behav Neurosci 2009, 123:1261-1270.
99. Watson G.B., Bolanowski M.A., Baganoff M.P., Deppeler C.L., Lanthorn T.H. d-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 1990, 510:158-160.
100. Wu S.L., Hsu L.S., Tu W.T., Wang W.F., Huang Y.T., Pawlak C.R., et al. Effects of d-cycloserine on the behavior and ERK activity in the amygdala: role of individual anxiety levels. Behav Brain Res 2008, 187:246-253.
101. Wullner U., Brouillet E., Isacson O., Young A.B., Penney J.B. Glutamate receptor binding sites in MPTP-treated mice. Exp Neurol 1993, 121:284-287.
102. Xavier L.L., Viola G.G., Ferraz A.C., Da Cunha C., Deonizio J.M., Netto C.A., et al. A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area. Brain Res Protoc 2005, 16:58-64.
103. Yaka R., Biegon A., Grigoriadis N., Simeonidou C., Grigoriadis S., Alexandrovich A.G., et al. d-Cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J 2007, 21:2033-2041.
104. Yasuda Y., Shimoda T., Uno K., Tateishi N., Furuya S., Yagi K., et al. The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J Neuroimmunol 2008, 204:43-51.
105. Zalcman S.S. Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity. Brain Res 2001, 899:1-9.
106. Zhang W.N., Pothuizen H.H., Feldon J., Rawlins J.N. Dissociation of function within the hippocampus: effects of dorsal, ventral and complete excitotoxic hippocampal lesions on spatial navigation. Neuroscience 2004, 127:289-300.